These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 22293142)

  • 1. Postrepolarization refractoriness in acute ischemia and after antiarrhythmic drug administration: action potential duration is not always an index of the refractory period.
    Coronel R; Janse MJ; Opthof T; Wilde AA; Taggart P
    Heart Rhythm; 2012 Jun; 9(6):977-82. PubMed ID: 22293142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postrepolarization refractoriness in acute ischemia and after antiarrhythmic drug administration.
    Pandit SV; Noujaim SF; Jalife J
    Heart Rhythm; 2012 May; 9(5):e13-4; author reply e14. PubMed ID: 22426151
    [No Abstract]   [Full Text] [Related]  

  • 3. Postrepolarization refractoriness: a mechanism in need for a molecule?
    Kirchhof P; Fabritz L
    Heart Rhythm; 2012 Jun; 9(6):983-4. PubMed ID: 22334152
    [No Abstract]   [Full Text] [Related]  

  • 4. Ischemic modulation of vulnerable period and the effects of pharmacological treatment of ischemia-induced arrhythmias: a simulation study.
    Cimponeriu A; Starmer CF; Bezerianos A
    IEEE Trans Biomed Eng; 2003 Feb; 50(2):168-77. PubMed ID: 12665030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects.
    Kirchhof PF; Fabritz CL; Franz MR
    Circulation; 1998 Jun; 97(25):2567-74. PubMed ID: 9657478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates.
    Roden DM
    Am J Cardiol; 1996 Aug; 78(4A):12-6. PubMed ID: 8780324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranolazine in Cardiac Arrhythmia.
    Saad M; Mahmoud A; Elgendy IY; Richard Conti C
    Clin Cardiol; 2016 Mar; 39(3):170-8. PubMed ID: 26459200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced post-repolarization refractoriness as an antiarrhythmic principle and its underlying mechanism.
    Franz MR; Gray RA; Karasik P; Moore HJ; Singh SN
    Europace; 2014 Nov; 16 Suppl 4():iv39-iv45. PubMed ID: 25362169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed repolarization as antiarrhythmic action.
    Olsson SB; Edvardsson N
    Eur Heart J; 1988 Feb; 9 Suppl B():37-43. PubMed ID: 3286265
    [No Abstract]   [Full Text] [Related]  

  • 11. Ionic mechanisms of ischemia-related ventricular arrhythmias.
    Ducceschi V; Di Micco G; Sarubbi B; Russo B; Santangelo L; Iacono A
    Clin Cardiol; 1996 Apr; 19(4):325-31. PubMed ID: 8706374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrophysiologic profile of dronedarone on the ventricular level: beneficial effect on postrepolarization refractoriness in the presence of rapid phase 3 repolarization.
    Milberg P; Frommeyer G; Uphaus T; Kaiser D; Osada N; Breithardt G; Eckardt L
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):92-100. PubMed ID: 21964157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opposite change with ischaemia in the antifibrillatory effects of class I and class IV antiarrhythmic drugs resulting from the alteration in ion transmembrane exchanges related to depolarization.
    Aupetit JF; Bui-Xuan B; Kioueh I; Loufoua J; Frassati D; Timour Q
    Can J Physiol Pharmacol; 2000 Mar; 78(3):208-16. PubMed ID: 10721812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiologic basis for arrhythmias in ischemic heart disease.
    Lazzara R; Scherlag BJ
    Am J Cardiol; 1984 Feb; 53(5):1B-7B. PubMed ID: 6364766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why are some antiarrhythmic drugs proarrhythmic? Cardiac arrhythmia study by bifurcation analysis.
    Chay TR
    J Electrocardiol; 1995; 28 Suppl():191-7. PubMed ID: 8656110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lidocaine does not affect myocardial electrical heterogeneity: implications for low proarrhythmic actions.
    Sims JJ; Winecoff AP; Ujhelyi MR
    Pharmacotherapy; 1997; 17(6):1267-73. PubMed ID: 9399610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.
    Belardinelli L; Liu G; Smith-Maxwell C; Wang WQ; El-Bizri N; Hirakawa R; Karpinski S; Li CH; Hu L; Li XJ; Crumb W; Wu L; Koltun D; Zablocki J; Yao L; Dhalla AK; Rajamani S; Shryock JC
    J Pharmacol Exp Ther; 2013 Jan; 344(1):23-32. PubMed ID: 23010360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cardiac ion channels: relevance to management of arrhythmias.
    Roden DM; George AL
    Annu Rev Med; 1996; 47():135-48. PubMed ID: 8712768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New aspects of the electrophysiologic effect of antiarrhythmic agents].
    Antoni H; Weirich J
    Herz; 1990 Apr; 15(2):61-9. PubMed ID: 2188893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amiodarone-induced postrepolarization refractoriness suppresses induction of ventricular fibrillation.
    Kirchhof P; Degen H; Franz MR; Eckardt L; Fabritz L; Milberg P; Läer S; Neumann J; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2003 Apr; 305(1):257-63. PubMed ID: 12649377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.